NeoGenomics (NEO)

• Market cap: $1.21B
• 1 day: -0.95%
• 5 days: -5.05%
• 1 month: -1.88%
• 3 months: -43.00%
• 6 months: -31.93%
• Year to date: -43.00%
• 1 year: -38.92%
• 5 years: -64.23%
• 10 years: 95.43%
• Sector: Industrials
• Industry: Testing Laboratories

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

789% more call options, than puts

Call options by funds: $15.6M | Put options by funds: $1.76M

11% more capital invested

Capital invested by funds: $1.82B [Q3] → $2.02B (+$196M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

1.16% less ownership

Funds ownership: 96.68% [Q3] → 95.52% (-1.16%) [Q4]

6% less funds holding

Funds holding: 267 [Q3] → 250 (-17) [Q4]

20% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 96

33% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 33

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 70% upside
• Avg. target: $17.50 86% upside
• High target: $18 91% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Piper Sandler David Westenberg 44% 1-year accuracy 19 / 43 met price target	91% upside $18	Overweight Maintained	26 Feb 2025
B of A Securities Derik De Bruin 35% 1-year accuracy 7 / 20 met price target	70% upside $16	Neutral Maintained	19 Feb 2025
Needham Mike Matson 40% 1-year accuracy 50 / 124 met price target	91% upside $18	Buy Maintained	19 Feb 2025
Goldman Sachs Matthew Sykes 43% 1-year accuracy 16 / 37 met price target	91% upside $18	Buy Maintained	28 Jan 2025